Marksans Pharma Ltd.

Date: August 12, 2026

BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other regulations, if applicable, we enclose herewith the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 approved by the Board of Directors of the Company at its Meeting held today i.e. August 12, 2026 along with Limited Review Reports thereon.

Pursuant to Regulation 33 of the Listing Regulations as amended, we hereby declare that M/s. MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 with an unmodified opinion.

The aforesaid information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html

The meeting commenced at 10:50 a.m. and concluded at 12:10 p.m.

We request you to note the aforesaid in your records.

Thanking You,

Yours faithfully,
For **Marksans Pharma Limited**

H PANIGRAHI
Digitally signed by H PANIGRAHI
Date: 2026.08.12 12:10:44 +05'30'

Harshavardhan Panigrahi
Company Secretary
Encl. As Above

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

HO
602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

Independent Auditor's Review Report on Standalone unaudited financial results of Marksans Pharma Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Marksans Pharma Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Marksans Pharma Limited (hereinafter referred to as 'the Company') for the quarter ended 30 June 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Nitin Tiwari
Partner
Membership No.:118894
UDIN: 26118894REJHBI3286

MSKA & ASSOCIATES LLP Chartered Accountants

Place: Mumbai
Date:12 August 2026

MARKSANS PHARMA LIMITED

CIN: L24110MH1992PLC066364

Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri [West], Mumbai-400053

Telephone No.: 022-4001 2000, Website: www.marksanspharma.com, E-mail: companysecretary@marksanspharma.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(₹ in million except per equity share data)

Sr. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30 June 2026	31 March 2026	30 June 2025	31 Mar 2026
		(UNAUDITED)	(AUDITED) (Refer Note 3)	(UNAUDITED)	(AUDITED)
1	Revenue from operations	3,211.87	3,615.73	3,197.34	13,414.76
2	Other income, net (Refer note 5)	174.70	274.75	20.10	1,035.33
3	**Total Income (1+2)**	3,386.57	3,890.48	3,217.44	14,450.09
	Expenses				
A	Cost of materials consumed	1,416.43	1,594.82	1,452.77	6,024.27
B	Purchase of stock-in-trade	180.26	132.59	227.98	730.62
C	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(18.23)	25.84	(32.91)	32.95
D	Employee benefits expense	317.75	329.15	279.04	1,219.77
E	Finance costs	3.40	3.53	3.02	13.27
F	Depreciation and amortisation expense	87.76	87.56	81.88	342.30
G	Other expenses	494.62	473.41	569.92	2,171.48
4	**Total Expenses**	2,481.99	2,646.90	2,581.70	10,534.66
5	**Profit Before Tax (3-4)**	904.58	1,243.58	635.74	3,915.43
	Tax Expense:				
	(a) Current tax	213.90	301.08	145.38	851.21
	(b) Current tax for earlier period	(0.10)	-	-	11.70
	(c) Deferred tax	0.41	23.27	9.80	45.54
6	**Total Tax Expense**	214.21	324.35	155.18	908.45
7	**Profit After Tax (5-6)**	690.37	919.23	480.56	3,006.98
	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurements of the net defined benefit plans	3.48	3.44	(1.01)	13.91
	Tax on above	(0.88)	(0.87)	0.25	(3.50)
8	**Other Comprehensive Income**	2.60	2.57	(0.76)	10.41
9	**Total Comprehensive Income (7+8)**	692.97	921.80	479.80	3,017.39
10	Paid up Equity Share Capital (face value ₹1 each fully paid)	453.16	453.16	453.16	453.16
11	Other equity				16,069.94
12	Earnings per equity share of ₹1 each*				
	Basic	1.52	2.03	1.06	6.64
	Diluted	1.52	2.03	1.06	6.63

* EPS is not annualised for the quarter ended 30 June 2026, 31 March 2026 and 30 June 2025.

MARKSANS PHARMA LIMITED

NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

1 The standalone unaudited financial results of the Company for the quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 August 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 ('the Regulations'), as amended and expressed an unmodified conclusion.

2 The standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations.

3 The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025, being the date of the end of the third quarter of the financial year which were subjected to limited review by the statutory auditor of the Company.

4 The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments.

5 Other income net includes net gain on foreign exchange differences amounting to Rs. 104.78 millions for the quarter ended 30 June 2026 (31 March 2026: net gain of Rs. 219.14 millions, 30 June 2025: net loss of Rs. 37.73 millions, year ended 31 March 2026: net gain of Rs. 474.26 millions).

6 During the current quarter, the Company has acquired 100% share capital of QliniQ B.V., a company based in Netherlands, for a consideration of EUR 7.50 Million. QliniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of prescription medicines and medical devices.

7 Subsequent to the quarter ended 30 June 2026, the Company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million. The acquisition was subsequently completed, following which ABCnow GmbH became a wholly owned subsidiary of the Company.

8 During the quarter ended 30 June 2026, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiary companies. Each stock option is exercisable into one equity share of the Company having a face value of ₹1 each.

9 The above standalone unaudited financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

MARKSANS PHARMA LTD. MUMBAI-53

Mark Saldanha
Chairman & Managing Director
DIN: 00020983

Date : 12 August 2026
Place: Mumbai
www.marksanspharma.com

NSKA & ASSOCIATES Chartered Accountants

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

HO
602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

Independent Auditor's Review Report on consolidated unaudited financial results of Marksans Pharma Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Marksans Pharma Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Marksans Pharma Limited hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended 30 June 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Marksans Pharma (UK) Limited	Wholly owned subsidiary
2	Relonchem Limited	Wholly owned subsidiary of Marksans Pharma (UK) Limited
3	Marksans Holdings Limited	Wholly owned subsidiary of Marksans Pharma (UK) Limited
4	Bell, Sons and Co. (Druggists) Limited	Wholly owned subsidiary of Marksans Holdings Limited

Sr. No	Name of the Entity	Relationship with the Holding Company
5	Marksans Pharma Inc.	Wholly owned subsidiary
6	Time-Cap Laboratories Inc.	Wholly owned subsidiary of Marksans Pharma Inc.
7	Marise Ann Inc.	Wholly owned subsidiary of Marksans Pharma Inc.
8	Custom Coating Inc.	Wholly owned subsidiary of Time-Cap Laboratories Inc.
9	Marksans Realty LLC	Wholly owned subsidiary of Time-Cap Laboratories Inc.
10	Nova Pharmaceuticals Australasia Pty Ltd	Subsidiary (60% Holding)
11	Nova Pharmaceuticals Limited	Wholly owned subsidiary of Nova Pharmaceuticals Australasia Pty Ltd
12	Access Healthcare for Medical Products L.L.C.	Wholly owned subsidiary
13	Marksans Pharma GmbH	Wholly owned subsidiary
14	Marksans Pharma (Europe) Limited, Ireland	Wholly owned subsidiary
15	Marksans (Canada), Inc.	Wholly owned subsidiary
16	QliniQ B.V.	Wholly owned subsidiary w.e.f. 1 April 2026

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the financial information of seven subsidiaries which have not been reviewed by their auditors, whose interim financial information, before giving effect to the consolidation adjustments, reflects total revenue of Rs. 1,305.28 million, total net profit after tax of Rs. 95.13 million and total comprehensive income of Rs. 95.13 million for the quarter ended 30 June 2026, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the

MSKA & ASSOCIATES LLP Chartered Accountants information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial information certified by the management.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Nitin Tiwari
Partner
Membership No.: 118894
UDIN: 26118894OLZOUN9502

Place: Mumbai
Date: 12 August 2026

MARKSANS PHARMA LIMITED
CIN: L24110MH1992PLC066364
Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri [West], Mumbai-400053
Telephone No.: 022-4001 2000, Website: www.marksanspharma.com, E-mail: companysecretary@marksanspharma.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(₹ in million except per equity share data)

Sr. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30 June 2026	31 March 2026	30 June 2025	31 Mar 2026
		(UNAUDITED)	(AUDITED) (Refer Note 3)	(UNAUDITED)	(AUDITED)
1	Revenue from operations	8,407.96	8,561.14	6,199.89	29,509.38
2	Other income, net (Refer note 5)	254.04	351.74	56.41	825.33
3	**Total Income (1+2)**	8,662.00	8,912.88	6,256.30	30,334.71
	Expenses				
A	Cost of materials consumed	2,206.69	2,649.72	1,926.94	9,592.08
B	Purchase of stock-in-trade	1,384.49	1,498.11	1,715.47	4,544.88
C	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(156.52)	(241.30)	(1,024.29)	(1,364.17)
D	Employee benefits expense	1,142.94	1,067.56	983.85	4,209.34
E	Finance costs	70.04	63.10	60.65	241.25
F	Depreciation and amortisation expense	248.64	242.87	231.01	986.32
G	Other expenses	1,700.01	1,632.84	1,596.69	6,519.46
4	**Total Expenses**	6,596.29	6,912.90	5,490.32	24,729.16
5	**Profit Before Tax (3-4)**	2,065.71	1,999.98	765.98	5,605.55
	Tax Expense:				
	(a) Current tax	518.94	555.49	196.08	1,499.64
	(b) Current tax for earlier period	(0.10)	20.17	-	30.34
	(c) Deferred tax	(47.20)	(66.00)	(12.12)	(125.07)
6	**Total Tax Expense**	471.64	509.66	183.96	1,404.91
7	**Profit After Tax (5-6)**	1,594.07	1,490.32	582.02	4,200.64
	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Remeasurements of the net defined benefit plans	3.48	3.44	(1.01)	13.91
	Tax on above	(0.88)	(0.87)	0.25	(3.50)
	Items that will be reclassified to profit or loss				
	Foreign currency translation reserve (net)	167.64	536.83	666.05	1,751.07
8	**Other Comprehensive Income**	170.24	539.40	665.29	1,761.48
9	**Total Comprehensive Income (7+8)**	1,764.31	2,029.72	1,247.31	5,962.12
	Net Profit attributable to:-				
	Owners of the Company	1,571.67	1,481.29	583.17	4,179.00
	Non-Controlling interests	22.40	9.03	(1.15)	21.64
	Other Comprehensive Income attributable to:-				
	Owners of the Company	166.90	518.64	653.03	1,712.59
	Non-Controlling interests	3.34	20.76	12.26	48.89
	Total Comprehensive Income attributable to:-				
	Owners of the Company	1,738.57	1,999.93	1,236.20	5,891.59
	Non-Controlling interests	25.74	29.79	11.11	70.53
10	Paid up Equity Share Capital (face value ₹1 each fully paid)	453.16	453.16	453.16	453.16
11	Other equity				29,778.40
12	Earnings per equity share of ₹1 each*				
	Basic	3.47	3.27	1.29	9.22
	Diluted	3.47	3.27	1.29	9.22

* EPS is not annualised for the quarter ended 30 June 2026, 31 March 2026 and 30 June 2025.

MSKA & ASSOCIATES LLP Chartered Accountants

MARKSANS PHARMA LTD. MUMBAI-63

MARKSANS PHARMA LIMITED

NOTES TO CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

1. The consolidated unaudited financial results of the Company for the quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 August 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 ('the Regulations'), as amended and expressed an unmodified conclusion.

2. The consolidated unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations.

3. The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025, being the date of the end of the third quarter of the financial year which were subjected to limited review by the statutory auditor of the Company.

4. The Group has a single business segment 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments.

5. Other income net includes net gain on foreign exchange differences amounting to Rs. 120.01 millions for the quarter ended 30 June 2026 (31 March 2026: net gain of Rs. 247.99 millions, 30 June 2025: net loss of Rs. 38.93 millions, year ended 31 March 2026: net gain of Rs. 500.95 millions).

6. During the current quarter, the Company has acquired 100% share capital of QliniQ B.V., a company based in Netherlands, for a consideration of EUR 7.50 Million. QliniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of prescription medicines and medical devices. QliniQ B.V. is a subsidiary of the company w.e.f. 1 April 2026. As per Ind AS 103 on 'Business Combinations', purchase consideration has been allocated on a provisional basis, pending final determination of the fair value of the acquired assets and liabilities.

7. Subsequent to the quarter ended 30 June 2026, the Company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million. The acquisition was subsequently completed, following which ABCnow GmbH became a wholly owned subsidiary of the Company.

8. During the quarter ended 30 June 2026, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiary companies. Each stock option is exercisable into one equity share of the Company having a face value of ₹1 each.

9. The above consolidated unaudited financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

MARKSANS PHARMA LTD. MUMBAI-63

Mark Saldanha
Chairman & Managing Director
DIN: 00020983

Date : 12 August 2026
Place: Mumbai
www.marksanspharma.com

MSKA & ASSOCIATES LLP Chartered Accountants